Prevalence of Renal Osteodystrophy and its Related Factors among Patients with End-Stage Renal Disease Undergoing Hemodialysis: Single Center Experience from Kermanshah, Iran
Objectives: The current study aimed to determine the prevalence of Renal Osteodystrophy (ROD) and its related factors in a group consisting of End-Stage Renal Disease (ESRD) patients undergoing maintenance hemodialysis. Methods: One hundred twenty –eight ESRD patients (52 men & 76 women) with a mean age of 59.3 years old undergoing maintenance hemodialysis at Imam Reza Referral Hospital, were included in this cross-sectional study. Thereafter, serum parathyroid hormone (PTH) levels were measured, and the range of 150 to 300 pg/mL was determined as the desirable range for the values. Values lower or higher than this range were used to determine ROD. Furthermore, this study investigated the association of ROD with clinical and laboratory variables (age at the onset of renal failure, hemodialysis sessions per week, clinical symptoms associated with renal osteodystrophy, and serum calcium and phosphate levels). Results: ROD was diagnosed in 93 patients (72.7%) out of 128 patients studied. Of them, 53 (41.4%) patients had PTH levels above 300 pg/mL (high bone turnover, HTO group) and 40 patients (31.3%) had PTH levels below 150 pg/mL (low bone turnover, LTO group). No statistically significant difference was detected in terms of ROD-related clinical findings (P=0.11), age at the time of ESRD diagnosis (P=0.2), and number of hemodialysis sessions per week (P=0.2). Hyperphosphatemia (52 patients, 57.1%) was more prevalent in ROD group compared with 11 patients (31.4%) included in the group without ROD (P=0.004). Conclusion: The prevalence rate of ROD in this study was found to be significant, and it was largely consistent with the rate reported in the research previously performed in some Asian countries. Hyperphosphatemia were laboratory variables closely related to ROD.